Market Newsdesk

MIAMI, April 16, 2025 (GLOBE NEWSWIRE) — EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80^th Emerging Growth Conference on April 16 & 17, 2025.

The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

Register for the Conference here.

Submit Questions for any of the presenting companies to:
[email protected]

For updates, follow us on Twitter

Day 1 – Today
April 16, 2025

9:00
Virtual Lobby opens.
Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.

9:20
Introduction

9:25 – 9:35
Empire Energy (ASX: EEG)
Keynote speaker: Alex Underwood, CEO & Managing Director

9:40 – 10:10
PSQ Holdings, Inc. (NYSE: PSQH)
Keynote speaker: Michael Seifert, Founder, President / CEO

10:50 – 11:20
Ur-Energy (NYSE American: URG) (TSX: URE)
Keynote speaker: John W. Cash, CEO

11:25 – 11:55
Interstellar Communication Holdings
Keynote speakers: Seda Hewitt, Space Ambassador of icMercury, Harri Laitinen, Lifeguard of icMercury, and Lijie Zhu, Captain of icMercury

12:00 – 12:30
U.S. Energy Corporation (NASDAQ: USEG)
Keynote speaker: Ryan Smith, President, CEO & Director

12:35 – 1:05
Odyssey Marine Exploration, Inc. (NASDAQ: OMEX)
Keynote speaker: Mark D. Gordon, Chairman & CEO

1:10 – 1:40
Nova Minerals Limited (NASDAQ: NVA) (ASX: NVA)
Keynote speaker: Christopher Gerteisen – CEO & Executive Director

1:45 – 2:15
C3 Metals Inc. (TSXV: CCCM) (OTCQB: CUAUF)
Keynote speaker: Daniel A. Symons, President, CEO & Director

2:20 – 2:50
Ucore Rare Metals, Inc. (OTCQX: UURAF) (TSXV: UCU)
Keynote speaker: Pat Ryan, CEO

2:55 – 3:05
Eloro Resources, Ltd. (OTCQX: ELRRF) (TSX: ELO)
Keynote speaker: Chris Holden – VP Corporate Development

3:10 – 3:20
Opawica Explorations Inc. (OTCQB: OPWEF) (TSXV: OPW)
Keynote speaker: Blake Morgan, President / CEO

3:25 – 3:35
HydroGraph Clean Power Inc. (OTCQB: HGRAF) (CSE: HG)
Keynote speaker: Kjirstin Breure, President and CEO

3:40 – 3:50
GeoVax Labs, Inc. (NASDAQ: GOVX)
Keynote speaker: David Dodd, Chairman, President / CEO

_______________________________________________________________

Day 2 – Tomorrow
April 17, 2025

8:45
Virtual Lobby opens.
Register for the Conference. If you already registered, go back to the registration link and click “Already registered” and enter your email.

9:00
Introduction

9:05 – 9:35
SBC Medical Group Holdings, Inc. (NASDAQ: SBC) 
Keynote speaker: Yuya Yoshida, Executive Vice President & CFO

10:50 – 11:20
Evofem Biosciences, Inc. (OTCQB: EVFM)
Keynote speaker: Amy Raskopf, Chief Business Development Officer

11:25 – 11:55
Bioxytran, Inc. (OTCQB: BIXT) 
Keynote speakers: Dr. David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

12:00 – 12:30
Clene Inc., (NASDAQ: CLNN)
Keynote speaker: Rob Etherington, President / CEO

12:35 – 1:05
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
Keynote speaker: Kraig Higginson – CEO

1:10 – 1:40
Regen BioPharma Inc. (OTC Pink: RGBP)
Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant

1:45 – 2:15
Banzai International, Inc. (NASDAQ: BNZI)
Keynote speaker: Joseph Davy, Co-Founder, Chairman & CEO

2:55 – 3:05
Citizens, Inc. (NYSE: CIA)
Keynote speakers: Jon Stenberg, President / CEO, and Jeff Conklin, CFO

3:10 – 3:20
Sono Group N.V. (OTCQB: SEVCF)
Keynote speaker: George O’Leary, Managing Director, CEO and CFO

Postponed
22nd Century Group, Inc. (NASDAQ: XXII)
Keynote speaker: Lawrence D. Firestone, Chairman & CEO

3:40 – 3:50
Alt Equity
Keynote speaker: Daniel Wait, President / Founder

3:55 – 4:05
Cyios Corp. (OTC Pink: CYIO)
Keynote speaker: John O’Shea, Chairman

4:10 – 4:20
Beneficient (NASDAQ: BENF)
Keynote speaker: Brad K. Heppner, CEO

Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

Register for the Conference here.

Submit Questions for any of the presenting companies to:
[email protected]

Replays: Subscribe to our YouTube Channel

About EmergingGrowth.com
Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

If you believe or know of a company that might fit our audience, contact us here.

Thank you for your interest in our conference, and we look forward to your participation in future conferences.

Contact:

Emerging Growth
Phone: 1-305-330-1985
Email: [email protected]

WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 65,000 shares of EyePoint common stock to four new employees. The stock options were granted on April 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $5.67 per share, the closing price of EyePoint’s common stock on April 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

For EyePoint:

Investors:

Christina Tartaglia
Precision AQ
Direct: 212-698-8700
[email protected]

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
[email protected]

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) — Tilray Beverages, a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce that its U.S. Beverage division has achieved a significant milestone, ranking #4 on the Brewers Association 2024 annual report of top 50 craft brewing companies in the U.S., based on beer sales volume. This marks a notable rise from its previous position at #5, reflecting the company’s continued growth and success in the craft brewing industry. Additionally, Tilray is proud to be ranked #12 in the top 50 overall brewing companies in the U.S.

Ty Gilmore, President, Tilray Beverages, North America, said, “We are incredibly proud to rank #4 on the Brewers Association list of top 50 craft brewing companies in the U.S. This achievement is a testament to the hard work and dedication of our team and the strong portfolio of craft brands that resonate with consumers. In a short period of time, we’ve grown our beer business to become a leading player in the industry, thanks to our commitment to quality and innovation. As we continue to grow our diverse range of craft beers through innovation that connects with consumers, we look forward to continued growth and future opportunities for Tilray Beverages.”

Tilray Brands’ U.S. Beer brands includes a diverse range of beloved craft brands such as SweetWater Brewing Company, Montauk Brewing Company, Alpine Beer Company, Green Flash Brewing Company, Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewing Company, Widmer Brothers Brewing, Square Mile Cider Company, Hop Valley Brewing Company, Terrapin Beer Company, Revolver Brewing, and Atwater Brewery. These brands have been instrumental in driving Tilray’s success and establishing its position as a leader in the craft brewing industry.

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would,” “ahead,” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. 

For more information:

Media: [email protected]

Investors: [email protected]

CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company’s founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal’s Board of Directors. Succeeding her, David Soergel, M.D., has been appointed Executive Vice President, Chief Medical Officer, effective April 21, 2025.

After teaching Genetics and Medicine at the University of Pennsylvania, where she was one of the youngest women at that time to become a fully tenured Professor, Dr. Taub moved into senior R&D leadership roles at Bristol Myers Squibb and Roche. In 2011, she co-founded Madrigal with a vision to address unmet medical needs for patients with serious liver and cardiometabolic diseases. Under her leadership, the company achieved an unprecedented milestone – the development of the first FDA-approved medicine for the treatment of MASH, Rezdiffra™ (resmetirom).

“Becky’s visionary leadership and relentless commitment have been instrumental in Madrigal’s success and the success of the MASH field,” said Bill Sibold, Chief Executive Officer of Madrigal. “Her pioneering work as both a scientist and entrepreneur led to the development and approval of Rezdiffra – the first-ever FDA-approved medicine for MASH – bringing real hope to patients who previously had no options. We are incredibly grateful for her contributions and are fortunate to have her continued guidance as a strategic advisor and Madrigal board member. Becky represents the best of what our industry is capable of, and I hope her story will serve as an inspiration for people beginning their careers in biopharma.”

“As Becky moves into her new role, we’re thrilled to welcome David Soergel to Madrigal,” said Sibold. “Dave brings more than 20 years of leadership experience in metabolic and cardiovascular disease drug development, spanning both biotech and large pharma. As we look to build a pipeline beyond Rezdiffra, Dave’s deep clinical development expertise and strong track record of advancing therapies across multiple therapeutic areas is exactly the kind of experience that aligns with where we’re taking the company.”

“I’d like to thank my colleagues, our research partners, and the many patients in the MASH community who have made invaluable contributions to Madrigal’s success,” said Dr. Taub. “What started as a small team of fewer than 10 R&D professionals in Conshohocken, PA is now a commercial-stage biopharma company with more than five hundred employees across the U.S. and Europe. I look forward to supporting Dave in my role as a scientific and medical advisor as Madrigal enters its next phase.”

Dr. Soergel joins Madrigal from Novartis, where he served as the Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. At Novartis, Dave led teams that designed and implemented evidence generation programs supporting the expansion of Entresto’s indications and uses. Additionally, he advanced novel medicines to approval for cardiovascular and renal diseases, including Leqvio, Fabhalta and Vanrafia, and served as the development lead for the acquisitions of the Medicines Company and Chinook Therapeutics. Prior to Novartis, Dr. Soergel held leadership roles at biotechnology companies, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, where he was responsible for the development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology, and heart failure and transplant at Johns Hopkins Hospital and the Children’s Hospital of Philadelphia.

“It is a great privilege to be succeeding Becky as Chief Medical Officer and I look forward to tapping into her expertise and guidance as I begin my new role at Madrigal,” said Dr. Soergel. “I’m excited to be joining an R&D team that delivered the first approved therapy in a disease that has been a major challenge for drug development. With two fully enrolled outcomes studies of Rezdiffra underway, Madrigal is at the forefront of scientific innovation in MASH, and the company is well-positioned to build on its leadership position through pipeline expansion.”

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.

Forward-Looking Statements

This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to Madrigal’s plans to expand its pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to enter into any strategic transactions to expand its pipeline and its ability to complete any such transactions; risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; the challenges with the commercial launch of a new product, particularly for a company that does not have commercial experience; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; enrollment and trial conclusion uncertainties; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission(“SEC”), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Investor Contact

Tina Ventura, [email protected]

Media Contact

Christopher Frates, [email protected]